Literature DB >> 21686343

Low molecular weight heparin (enoxaparin) reverses pregangrene in a preterm neonate.

Jayendra R Gohil1, Dhaval I Solanki, Lalji Vaghjiyani.   

Abstract

A 34-week-old, 1.6 kg preterm boy was admitted for management of mild respiratory distress syndrome. On the third day of life 1 min after an intravenous cannulation attempt at the right cubital fossa, he developed pregangrene bluish discoloration of all fingertips up to the distal interphalangial joint and pallor of right palm. Pulsations on right forearm were reduced. There was no evidence of sepsis.Enoxaparin, a low molecular weight heparin (1.5 mg/kg (standard dose)) was injected subcutaneously in the abdomen in two doses 12 h apart within 2 h of the event. At 6 h after the first dose, brachial artery pulsation was bilaterally symmetrical. After the second dose, bilateral radial artery pulsation became symmetrical. The pregangrene changes returned to normal within 20 h as the distal phalanges became pink and warm. He was discharged on the eighth day of life. Enoxaparin was safe and effective in this preterm infant for reversal of pregangrene.

Entities:  

Year:  2009        PMID: 21686343      PMCID: PMC3027785          DOI: 10.1136/bcr.12.2008.1388

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  5 in total

1.  Low molecular weight heparin for neonatal thrombosis.

Authors:  A Shama; S K Patole; J S Whitehall
Journal:  J Paediatr Child Health       Date:  2002-12       Impact factor: 1.954

2.  Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.

Authors:  W Streif; G Goebel; A K C Chan; M P Massicotte
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-09       Impact factor: 5.747

3.  Risk factors for umbilical venous catheter-associated thrombosis in very low birth weight infants.

Authors:  Shalu Narang; Jason Roy; Timothy P Stevens; Meggan Butler-O'Hara; Craig A Mullen; Carl T D'Angio
Journal:  Pediatr Blood Cancer       Date:  2009-01       Impact factor: 3.167

4.  Enoxaparin use in the neonatal intensive care unit: experience over 8 years.

Authors:  Janet I Malowany; David C Knoppert; Anthony K C Chan; Dion Pepelassis; David S C Lee
Journal:  Pharmacotherapy       Date:  2007-09       Impact factor: 4.705

5.  Neonatal thrombosis.

Authors:  R Saxena; M Kannan; V P Choudhry
Journal:  Indian J Pediatr       Date:  2003-11       Impact factor: 1.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.